Nevotens (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nevotens, is a beta‑blocker presented as an oral tablet for oral use. It belongs to the class of selective β1‑adrenergic receptor antagonists with nitric‑oxide mediated vasodilation and is prescribed to manage hypertension and heart failure in adult patients.

GNH USA supplies Nevotens as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for global markets. All batches are manufactured under stringent GMP standards to ensure product consistency.

Nebivolol is used in cardiovascular therapy to lower blood pressure and improve heart function, particularly in conditions where β‑blockade is beneficial. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Heart failure: improves left ventricular ejection fraction and reduces symptoms of chronic heart failure. - Post‑myocardial infarction: may help lower the risk of recurrent cardiac events.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue - Headache - Dizziness - Nausea

Serious or Rare Side Effects: - Severe bradycardia - Symptomatic hypotension - Bronchospasm

When prescribing Nebivolol, clinicians should consider several safety measures. - Monitor blood pressure: check regularly to ensure therapeutic response. - Assess heart rate: watch for excessive bradycardia, especially in patients with conduction disorders. - Use caution in asthma or COPD: β‑blockade may exacerbate bronchospasm. - Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. - Adjust dose in renal impairment: consider reduced dosing in patients with decreased renal function. - Store at room temperature: keep in original packaging, protect from moisture and light.

Nebivolol can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use with other β‑blockers: may cause additive bradycardia. - Calcium channel blockers verapamil or diltiazem: increase plasma levels and risk of heart block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol concentrations, leading to hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, monitor electrolytes. - NSAIDs: can reduce antihypertensive efficacy, check blood pressure. - Anti‑arrhythmic agents (e.g., amiodarone): may affect cardiac conduction.